Broadwood Partners, L.P. Purchases 31,780 Shares of STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical (NASDAQ:STAA) major shareholder Broadwood Partners, L.P. purchased 31,780 shares of the stock in a transaction dated Wednesday, April 2nd. The shares were acquired at an average price of $17.43 per share, for a total transaction of $553,925.40. Following the acquisition, the insider now directly owns 12,487,044 shares of the company’s stock, valued at $217,649,176.92. This represents a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Monday, March 31st, Broadwood Partners, L.P. bought 22,189 shares of STAAR Surgical stock. The stock was acquired at an average price of $17.46 per share, for a total transaction of $387,419.94.
• On Thursday, March 27th, Broadwood Partners, L.P. purchased 3,620 shares of STAAR Surgical stock. The shares were bought at an average price of $17.48 per share, with a total value of $63,277.60.
• On Tuesday, March 25th, Broadwood Partners, L.P. acquired 34,296 shares of STAAR Surgical stock. The stock was bought at an average price of $17.44 per share, for a total transaction of $598,122.24.
• On Thursday, March 20th, Broadwood Partners, L.P. purchased 108,720 shares of STAAR Surgical stock. The shares were bought at an average price of $17.96 per share, for a total transaction of $1,952,611.20.
• On Tuesday, March 18th, Broadwood Partners, L.P. acquired 93,124 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.54 per share, with a total value of $1,633,394.96.
• On Monday, March 3rd, Broadwood Partners, L.P. bought 249,503 shares of STAAR Surgical stock. The stock was purchased at an average price of $16.64 per share, for a total transaction of $4,151,729.92.
• On Thursday, February 27th, Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock. The shares were purchased at an average price of $17.05 per share, with a total value of $4,421,337.80.
• On Friday, February 14th, Broadwood Partners, L.P. acquired 36,532 shares of STAAR Surgical stock. The stock was purchased at an average price of $15.49 per share, for a total transaction of $565,880.68.
• On Wednesday, February 12th, Broadwood Partners, L.P. bought 259,616 shares of STAAR Surgical stock. The stock was acquired at an average price of $14.96 per share, with a total value of $3,883,855.36.
• On Thursday, January 16th, Broadwood Partners, L.P. purchased 8,221 shares of STAAR Surgical stock. The shares were acquired at an average price of $21.50 per share, for a total transaction of $176,751.50.

STAAR Surgical Trading Down 8.5 %

Shares of STAAR Surgical stock opened at $15.92 on Friday. The company has a market cap of $785.25 million, a price-to-earnings ratio of -38.83 and a beta of 0.75. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The company’s fifty day simple moving average is $18.82 and its 200-day simple moving average is $24.76.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. William Blair cut shares of STAAR Surgical from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 12th. BTIG Research lowered STAAR Surgical from a “buy” rating to a “neutral” rating in a report on Wednesday, February 12th. Canaccord Genuity Group reduced their target price on STAAR Surgical from $28.00 to $17.00 and set a “hold” rating for the company in a report on Thursday, February 13th. Stifel Nicolaus lowered their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, February 12th. Finally, Stephens restated an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a research note on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $25.29.

Institutional Trading of STAAR Surgical

Several hedge funds and other institutional investors have recently bought and sold shares of STAA. Broadwood Capital Inc. lifted its stake in shares of STAAR Surgical by 0.7% in the fourth quarter. Broadwood Capital Inc. now owns 10,848,631 shares of the medical instruments supplier’s stock valued at $263,513,000 after buying an additional 80,200 shares during the period. Vanguard Group Inc. raised its holdings in STAAR Surgical by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock valued at $142,232,000 after acquiring an additional 319,441 shares in the last quarter. State Street Corp lifted its position in shares of STAAR Surgical by 0.5% in the 3rd quarter. State Street Corp now owns 1,940,567 shares of the medical instruments supplier’s stock worth $72,092,000 after acquiring an additional 10,430 shares during the period. Resona Asset Management Co. Ltd. acquired a new stake in shares of STAAR Surgical during the 4th quarter worth approximately $36,411,000. Finally, Geode Capital Management LLC increased its position in shares of STAAR Surgical by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier’s stock valued at $43,641,000 after purchasing an additional 31,212 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.